TSHA Earnings Taysha Gene Therapies, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–21 of 21
| Q2 2026 | 2026-06-30 | -0.24 | 2026-08-11 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.12 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -0.34 | 2026-03-19 | 10-K |
| Q3 2025 | 2025-09-30 | -0.26 | 2025-11-04 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.17 | 2026-08-11 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.08 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -0.36 | 2026-03-19 | 10-K |
| Q3 2025 | 2024-09-30 | -0.29 | 2025-11-04 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.19 | 2025-08-12 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.10 | 2025-05-15 | 10-Q |
| FY 2024 | 2023-12-31 | -0.96 | 2025-02-26 | 10-K |
| Q3 2024 | 2023-09-30 | -1.88 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.66 | 2024-08-12 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.28 | 2024-05-14 | 10-Q |
| FY 2023 | 2022-12-31 | -3.78 | 2024-03-19 | 10-K |
| Q3 2023 | 2022-09-30 | -2.79 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -2.16 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -1.32 | 2023-05-11 | 10-Q |
| FY 2022 | 2021-12-31 | -4.64 | 2023-03-28 | 10-K |
| Q3 2022 | 2021-09-30 | -3.31 | 2022-11-08 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.96 | 2022-08-11 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.